NBIX
Neurocrine Biosciences Inc
138.90$
-0.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -192.2% | -707.9% | -58.4% | 22.5% | 18.7% | 21.8% | 22.6% | 22.8% | 20.7% | 25.3% | 27.4% | |
| – | 5.1% | 9.7% | 1.5% | 0.9% | 0.9% | 0.8% | 1.0% | 1.0% | 1.1% | 1.2% | 1.1% | |
| – | 143.6% | 189.8% | 26.3% | 12.9% | 9.6% | 9.6% | 11.8% | 11.6% | 10.3% | 8.3% | 7.6% | |
| – | 126.8% | 166.9% | 25.0% | 12.7% | 9.6% | -18.0% | 12.6% | 17.9% | – | – | – | |
| – | 44.0% | 38.5% | -5.4% | -0.4% | -0.6% | -3.6% | 1.5% | -4.5% | 1.5% | -0.8% | -4.5% | |
| – | 9.8% | 27.4% | 4.3% | 5.5% | 1.9% | 1.0% | 2.1% | 1.1% | 1.5% | 1.6% | 1.2% | |
| – | -990.5% | 753.0% | -155.5% | -53.8% | -26.8% | 0.4% | -11.5% | -11.9% | -24.8% | -5.4% | -9.2% | |
| – | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | 1,401.1% | 15.9% | 8.6% | 6.5% | 3.5% | 2.8% | 2.4% | 3.0% | 0.0% | -12.7% | -5.9% | |
| – | 2,543.3% | 3,351.9% | 311.1% | -41.4% | -23.7% | -17.9% | 0.0% | -18.7% | 0.0% | -13.1% | 0.0% | |
| – | 1,401.1% | 15.9% | 319.7% | 6.5% | 4.1% | -15.1% | 2.4% | -15.7% | 3.5% | -20.7% | -1.3% | |
| – | 218.4% | 61.1% | 105.8% | -24.8% | -4.0% | 7.2% | 13.6% | -4.9% | -0.6% | -0.8% | 16.8% | |
| – | -202.0% | -735.3% | -62.7% | 17.0% | 16.8% | 20.8% | 20.6% | 21.7% | 19.2% | 23.7% | 26.2% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.